Home / Transcripts / AbCellera Biologics Inc. (ABCL) · November 6, 2025

AbCellera Biologics Inc. (ABCL) Earnings Call Transcript

November 6, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 23 min

Earnings Call Speaker Segments

Tryn Stimart executive
#1

Thanks. Hi, everyone. We appreciate you being with us on the call for AbCellera's Q3 2025 earnings discussion. This is Tryn Stimart, serving as AbCellera's Chief Legal and Compliance Officer. Joining us today as well are Dr. Carl Hansen, who is AbCellera's President and CEO, and Andrew Booth, AbCellera's Chief Financial Officer. On this call, we expect to share projections and forward-looking statements grounded in what we currently anticipate, made under the Safe Harbor protections of the Private Securities Litigation Reform Act of 1995. Because of a number of factors described in our most recent Form 10-K along with later Forms 10-Q and 8-K submitted to the Securities and Exchange Commission, our actual results might differ materially. AbCellera has no obligation to revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Our presentation today, our earnings press release, and our SEC filings can be found on our Investor Relations website. What we share regarding our pipeline is meant for the investment community and is not promotional. Before we move into our prepared remarks, please keep in mind that every dollar mentioned on the call is a U.S. dollar. Once our prepared remarks are done, we'll open the lines for questions and answers; with that, I'll hand the call to Carl.

Carl Hansen executive
#2

Thanks, Tryn, and I appreciate all of you being here with us today. During the prior quarter, we finished moving away from being a platform company and became a clinical-stage biotech, marked by kicking off phase I clinical trials for ABCL 635 and ABCL 575. Neither trial has hit any snags, and both should deliver readouts next year as planned. I'm happy to share that during this quarter, operations have begun at our new clinical manufacturing facility, and our platform investments are now substantially complete. We closed out the quarter with roughly $680 million in available liquidity to carry out our strategy, and with the year wrapping up, we feel confident about hitting all our corporate priorities, which includes moving at least one additional development candidate into IND enabling studies. One standout moment this quarter was bringing on Dr. Sarah Nunberg as Chief Medical Officer. Sarah is a physician scientist whose clinical drug development experience spans more than 20 years. She has a broad — excuse me — she has worked across a broad range of modalities and indications and has led programs through all stages of development, from discovery through to approval. Expect Sarah to be on future earnings calls to give updates on our clinical pipeline. With Sarah taking the helm, Dr. Jeff Nickel will be stepping down as our SVP of Development. I want to thank Jeff for his leadership in building development as we transitioned from a platform company to a clinical-stage biotech; with that, I will hand it over to Andrew to discuss our financials. Andrew?

Andrew Booth executive
#3

Thanks, Carl. As Carl mentioned, AbCellera remains well capitalized, holding about $520 million in cash and cash equivalents, along with roughly $160 million in committed government funding that's available to us as we carry out our strategy; we're still executing our plans, concentrating on internal programs and making the most of our CMC and GMP investments. Turning to our business metrics, during Q3 we kicked off work on one more partner-initiated program, bringing us to a cumulative 103 programs that include downstream participation. With phase I trials now running for ABCL 635 and ABCL 575, our cumulative count of molecules that have entered the clinic stands at 18, covering both our own pipeline and partner-led ones. As we've said before, we see the collective advancement of molecules in the clinic as a possible source of near- and mid-term revenue. Longer term, that comes through downstream milestone fees and royalty payments. Now to revenue and expenses: revenue this quarter came in at $9 million, mostly from research fees tied to work on partnered programs; that's against revenue of about $7 million in last year's comparable quarter. Regarding research fee revenue, as we've noted previously, we anticipate it will keep declining as our attention shifts more toward the internal pipeline. R&D expenses this quarter totaled $55 million, about $14 million above last year; that figure captures our emphasis on investing in internal and co-development programs. The rise relative to recent run-rate expense levels in Q3 stems mostly from specific investments totaling $15 million across two internal programs; on sales and marketing, Q3 expenses came in just under $3 million, a modest decrease versus the same quarter a year ago; for general administration, expenses reached approximately $22 million, versus roughly $19 million in Q3 of 2024. Those expenses include ongoing costs tied to defending our intellectual property. On earnings, we're posting a net loss of roughly $57 million this quarter, against a loss of about $51 million in the comparable quarter last year. On a per-share basis, that works out to a loss of $0.19 per share, both basic and diluted. Now cash flows: operating activities across the first nine months of 2025 consumed approximately $97 million in cash and equivalents. Leaving out investments in marketable securities, investment activities came to $49 million year to date. That's mainly property, plant, and equipment, reflecting investments to establish clinical manufacturing, which are now substantially complete, in line with what we expected. Government contributions partially offset those PP&E investments. Under our Treasury strategy, we have $413 million placed in short-term marketable securities. Investment activities this quarter included a $62 million net divestment from those holdings. All told, when the quarter closed, we held $523 million across total cash, cash equivalents, and marketable securities. Just to remind everyone, commitments for funding to move our internal pipeline forward have come in from the Government of Canada's Strategic Innovation Fund along with the Government of British Columbia. That capital we can access isn't reflected on our balance sheet, and when you combine over $520 million in cash and equivalents with the portion of our secured government funding not yet used, we've got roughly $680 million of available liquidity for carrying out our strategy. Beyond that, more liquidity is available through what we own — the lab and office buildings located in Vancouver, plus our GMP manufacturing facility — and neither of those appears on our balance sheet because both were financed off of it. Where operating cash usage is concerned for the rest of 2025, the priority stays on moving our two lead programs through their phase I clinical studies while also developing a robust pre-clinical pipeline. Looking at company expenditures overall, our capital needs remain quite manageable, and our belief is unchanged that liquidity on hand is enough to fund substantially past the coming three years of growing pipeline investments. We're glad to take your questions now. Operator?

Malcolm Hoffman analyst
#4

Malcolm Hoffman here, asking on behalf of Evan. Appreciate you taking the question. What I'd like to understand is how we should be thinking about those partner-initiated programs in the clinic. They've appeared fairly flat since 2024, and just to be clear, we're glad to see the shift toward more development led by AbCellera. I'm simply trying to grasp why those partner-initiated programs might not be advancing clinically. Is that purely a matter of timing? Then a second question regarding Dr. Nunberg and her new position as CMO. Could you speak to why you judged that now was the right moment to bring Dr. Nunberg in? What do you believe she brings to AbCellera that's unique, which the company might not have had previously? Thank you.

Carl Hansen executive
#5

Sure, happy to field that one. This is Carl Hansen. To start with the partner-initiated programs: as you're aware, during the company's early days and continuing up through 2023, our business centered mainly on a partnership model, under which we conducted discovery for partners while retaining a stake in the molecules that came out of it, through both royalties and milestones. A substantial number of those have been handed off, and per what Andrew said, I think roughly 103 programs have been initiated by us as of today. We do anticipate that a certain portion of them will advance into clinical development, and we'll keep reporting on that. What I'd say is that, in our experience, this has taken longer than we originally expected. We have instances where programs that got handed off ended up entering clinical development as many as six years afterward. It's hard to judge how many of them will eventually reach clinical development, yet we believe there's value sitting there that will build up over time, as Andrew noted during his prepared remarks. Turning to why we brought Sarah aboard: clearly, back in 2023, we reached the definitive choice to step away from that partnership business and instead pursue drug development for our own account. During the last few months, we managed to get the first two programs into clinical development. Behind those, we have a strong pipeline on the way. With the portfolio maturing, we firmly believed the moment had arrived to add a senior executive who has clinical development experience, and also that the company had reached a point where we could draw in somebody truly top-tier. Having Sarah with us is something we're delighted about, and we're eager to work alongside her and with all of you in the years ahead as the pipeline matures.

Malcolm Hoffman analyst
#6

We appreciate that, everyone, and thanks for hosting this call.

Andrew Booth executive
#7

Hello, all. Good evening, and I appreciate you taking my question. Carl, I wanted to ask whether you'd be open to discussing a bit the approach to disclosing data that you intend to use for the phase I 635 study, especially since you have the different cohorts — SAD, MAD, dosing — plus the proof of concept portion where efficacy is being assessed. I'm just curious whether all of this will be included in a single disclosure, and then whether you could help set expectations regarding the profile you'd consider supportive enough to keep moving this forward into a phase II study. I have one follow-up after that. Thank you.

Carl Hansen executive
#8

Appreciate that, Andrea. Regarding what you asked first, the plan is to put out one announcement once the proof of concept work wraps up — that's the double-blind, placebo-controlled study of ABCL 635 in the population of patients it's designed for. Our expectation is that this lands at some point in the new year. Previously, I believe we pointed to roughly the middle of the new year, though you should allow a couple of months of cushion on either side for the error bars. What we want to see is a safety signal plus efficacy demonstrating that we can compete with the other products already on the market. The trial has the statistical power to establish that. Around the halfway mark of next year, we ought to have a great deal of knowledge about this program. Thus far, what we're observing is encouraging. All of it remains on schedule. Should that hold, we will be poised to push it aggressively into later-stage studies.

Andrea Newkirk analyst
#9

Understood. All right. So assuming you hit the target product profile you're aiming for, once those results come out next year, how much of a validation would that be for the platform and the technology? And do you believe it carries through to the remainder of the pipeline?

Carl Hansen executive
#10

That's a wonderful question. As we've said previously, one of the fields in which we've put resources in for quite some time and where I think our capabilities are world-class is generating antibodies directed at ion channel and GPCR targets. NK3R, clearly, is a GPCR target, making it the first out of that platform to advance. To me, that's compelling proof the platform is functioning and that we're able to create highly differentiated molecules. Naturally, proof of a platform doesn't come from one asset alone, and we intend to keep following it up repeatedly with additional molecules from that pipeline that excite us just as much.

Andrew Booth executive
#11

Okay. Thanks so much for the call.

Carl Hansen executive
#12

Absolutely. Regarding enrollment, like I said, the program is progressing as anticipated, so all is on schedule and moving at the speed we expected. We aren't sharing preliminary data on how far dosing has progressed, but as I noted, what we're seeing is encouraging, and thus far, all is as anticipated. Okay. Great. Just one more quick thing. I know on the Q2 call you mentioned you were positioned to declare a possible fourth AbCellera-led candidate before this year ends. Are you still on track for that? Yes, that's right. I believe I stated during my prepared remarks that we remain on track to advance an additional development candidate before the year ends, and that would be the fourth in the pipeline. Okay. Great. Thanks for taking our questions.

Faisal Khurshid analyst
#13

Hey, everyone. Thanks for taking my question. Regarding 635, might you tell us if there's a particular benchmark or threshold you'd like to observe when it comes to testosterone reduction in healthy male volunteers?

Carl Hansen executive
#14

Absolutely. I won't commit to a particular number, though solid literature exists that reports testosterone levels for small molecules that had been in development, fezolinetant in particular. Given the study's power, we'd seek evidence showing engagement that's at minimum on par with that in order to proceed.

Faisal Khurshid analyst
#15

Understood. On top of that, might you speak to the danger involved in hitting this target with a MAB, since it is a CNS target?

Carl Hansen executive
#16

Absolutely. Absolutely. That is an excellent question. I believe I brought this up during a prior call; our view is that this pathway—NK3R—has very strong validation. Our position is that should we succeed in engaging NK3R within the pertinent neurons, the odds are high that the drug would be efficacious. Within the arcuate nucleus, NK3R is expressed in KNDy neurons. Such neurons link to the endocrine system and additionally cross the blood-brain barrier to reach the brain's thermoregulatory center. We anticipate being able to engage NK3R inside the arcuate nucleus. Based on what we know about the biology, our belief is that this ought to be enough to produce efficacy when treating VMS. Naturally, that has yet to be demonstrated, so we must await the proof of concept study along with its readout before we have the conviction needed to advance the program.

Faisal Khurshid analyst
#17

Understood. Thank you.

Steve Dechert analyst
#18

Hey, thanks, everyone. This is Steven, filling in for Scott. I wanted to see if you could discuss the advantages that 635 offers compared with the hormonal treatments already available for hot flashes. And then, as a follow-up, are any molecules in development right now that would be direct competitors to 635? Thank you.

Carl Hansen executive
#19

Sure. We aren't developing 635 to replace hormonal therapies. Instead, it's being developed as another option besides menopausal hormone therapy. As I believe I said on an earlier call, around 12% of women have a serious contraindication to menopausal hormone therapy. On top of that, roughly 8% stop treatment due to adverse events or tolerability. A substantial share of women have limited choices or are unable to use MHT, which is the first-line treatment for VMS; regarding other therapies, naturally, two molecules are approved at this point. One is Veozah from Astellas Pharma, and the other is elinzanetant from Bayer. Both of those are on the market now; that's our understanding. We're in a strong position with these two products available, offering solid options for patients who need such treatments and growing the market for us, so we can enter with a molecule that we think can be differentiated in dosing, in safety, and possibly in efficacy as well, depending on how we approach target engagement. Great.

Carl Hansen executive
#20

Right. So 575 clearly trails both Amlatilimab and Amgen's Rocatilimab. When we kicked off this program, the whole differentiation argument centered on giving doses less often. More recently, especially after the Coast trial data came out for Amlatilimab, the picture is that this class does work — just not to the degree people had hoped. Dupixent, in earlier studies, had performed better. It appears approval will come for it as a second-line treatment. On top of that, they demonstrated that dosing at one month and dosing at three months perform about the same. So today we hold a drug whose data point toward dosing that could be spaced out even further, maybe six months; whether that matters much in actual clinical practice isn't clear. Where we stand on 575 at the moment is this: we've got an excellent molecule. The initial data releases will demonstrate safety, naturally, and additionally PK along with half-life that back up that dosing theory. The biggest catalysts, though, will likely originate outside AbCellera; they'll be readouts involving Amlatilimab or the OX40, OX40 ligand class plus other indications that Sanofi and other parties are studying. Great. Thank you.

Carl Hansen executive
#21

I appreciate all of you being here with us right now. It's a thrilling moment for AbCellera, and as we head into 2026, we've got some really encouraging momentum in the pipeline — both for programs that are on their way and for what's already in the clinic; we're eager to share updates with you on upcoming calls. Many thanks.

Operator operator
#22

That wraps up the call for today. We appreciate everyone taking part, and have a great remainder of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete AbCellera Biologics Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to AbCellera Biologics Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.